Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-21-071533
Filing Date
2021-03-05
Accepted
2021-03-05 16:30:53
Documents
2
Period of Report
2020-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d132159d8ka.htm 8-K/A 19676
2 EX-99.1 d132159dex991.htm EX-99.1 53288
  Complete submission text file 0001193125-21-071533.txt   74071
Mailing Address 2280 INWOOD ROAD DALLAS TX 75235
Business Address 2280 INWOOD ROAD DALLAS TX 75235 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39536 | Film No.: 21718879
SIC: 2836 Biological Products, (No Diagnostic Substances)